News Release
melanoma

PHILADELPHIA— New research shows that testosterone promotes melanoma proliferation by activating a newly recognized nonclassical testosterone receptor in melanoma cells called ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any available therapeutics but is widely expressed in human melanoma. The new study from researchers at the Perelman School of Medicine at the University of Pennsylvania uses melanoma models in mice to show that drugs that target androgen receptors (AR) in prostate cancer can be effectively repurposed to block ZIP9 and thereby inhibit melanoma in men. The findings were published today in the journal Cancer Research.

Melanoma and most other cancers occur more frequently, and have worse outcomes, in men compared to women. The American Cancer Society estimates about 106,110 new melanomas will be diagnosed (about 62,260 in men and 43,850 in women) in the United States in 2021, and about 7,180 people are expected to die from the disease (about 4,600 men and 2,580 women). While this sex difference has been recognized for decades, the reasons for the difference have largely remained elusive. While sex steroids are thought to be involved, the classical androgen and estrogen receptors generally considered necessary for sex steroid effects are not detectable in most melanomas.

“The male sex hormone testosterone increases the rate of melanoma cell proliferation because it acts through ZIP9 rather than through the classical testosterone receptors that are well studied in prostate cancer,” said senior author Todd Ridky, MD, PhD, an associate professor of Dermatology at Penn. “While there are no approved drugs that inhibit ZIP9, structurally related drugs such as apalutamide that block the classical testosterone/androgen receptor in prostate cancer, when given to mice with melanoma, slowed tumor growth and extended survival, but only in males.”

This discovery regarding ZIP9 is likely applicable to most human melanomas. The study looked at 98 human melanocytic lesions (regular moles, as well as primary and metastatic melanoma from both males and females). Nearly all samples expressed lots of ZIP9, while the classical testosterone receptor was not detectable in any of them. ZIP9 is also expressed in many other human tissues, suggesting that this discovery in melanoma may be broadly applicable to many cancer types. 

This study is the first to show that ZIP9 is a determinant of the male vs. female disparity in cancer, and establishes a novel mechanistic link between male androgens and melanoma pathobiology. These findings also build on prior work from the Ridky lab at Penn, where researchers have shown that estrogen signaling through a nonclassical estrogen receptor called G protein-coupled estrogen receptor (GPER) suppresses melanoma and other cancers.

With regard to some cancers and sex hormones, biologic males seem to be disadvantaged twice: they lack the protective effects of nonclassical estrogen activity, while testosterone, through ZIP9, actively makes the tumors worse. The potential good news is that both of these sex steroid receptors are likely druggable. While more clinical trials are needed, currently approved prostate cancer drugs seem to effectively block ZIP9.

The study was supported by grants from the NIH/NCI (R01 CA163566, 11 R41CA228695), and by the Stiefel award from the Dermatology Foundation. This work was also supported in part by the Penn Skin Biology and Diseases Resource-based Center (P30- 13 AR069589), the Melanoma Research Foundation, and the Department of Defense.

Topic:

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.

Share This Page: